Benefits and Safety of Chinese Herbal Medicine in Treating Psoriasis: An Overview of Systematic Reviews

Background: In recent years, systematic reviews/meta-analyses (SRs/MAs) of Chinese herbal medicine (CHM) for psoriasis have continuously emerged. Their methods and evidence quality, however, are yet to be evaluated, and whether their conclusions can provide clinicians with reliable evidence is still...

Full description

Bibliographic Details
Main Authors: Jie Zhang, Qianying Yu, Li Peng, Yuesi Qin, Mingyi Jing, Dan Huang, Jing Guo, Min Xiao, Mingling Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-07-01
Series:Frontiers in Pharmacology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.680172/full
_version_ 1829503787436343296
author Jie Zhang
Jie Zhang
Qianying Yu
Li Peng
Li Peng
Yuesi Qin
Mingyi Jing
Mingyi Jing
Dan Huang
Dan Huang
Jing Guo
Min Xiao
Mingling Chen
author_facet Jie Zhang
Jie Zhang
Qianying Yu
Li Peng
Li Peng
Yuesi Qin
Mingyi Jing
Mingyi Jing
Dan Huang
Dan Huang
Jing Guo
Min Xiao
Mingling Chen
author_sort Jie Zhang
collection DOAJ
description Background: In recent years, systematic reviews/meta-analyses (SRs/MAs) of Chinese herbal medicine (CHM) for psoriasis have continuously emerged. Their methods and evidence quality, however, are yet to be evaluated, and whether their conclusions can provide clinicians with reliable evidence is still debatable.Objectives: This overview aims to evaluate the methodological quality, risk of bias, and reporting quality of relevant SRs/MAs, as well as the current evidence of CHM for treating psoriasis.Methods: We searched nine electronic databases from their respective time of establishment to January 20, 2021, as well as the reference lists of the included SRs/MAs, protocol registries, and gray literature. Two reviewers independently used the following: A Measurement Tool to Assess Systematic Reviews (AMSTAR) 2, Risk of Bias in Systematic Reviews (ROBIS), the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA), and Grades of Recommendations, Assessment, Development and Evaluation (GRADE) to evaluate the methodological quality, risk of bias, reporting quality, and evidence quality of the included SRs/MAs.Results: This review included 14 SRs/MAs involving 45 outcomes, of which 12 (85.71%) SRs/MAs had a very low quality evaluated by AMSTAR 2 and 7 (50.00%) SRs/MAs had a high risk of bias assessed by ROBIS. The protocol and registration and funding statements were the major reporting flaws according to the PRISMA checklist. The evaluation with the GRADE system demonstrated no outcome of high-quality evidence, and inconsistent efficacy evaluations were found in this overview. Only 15 (33.33%) outcomes were moderate-quality evidence, supporting the claim that CHM plus Western medicine (WM) was superior to WM. Generally low quality of evidence showed no difference in the incidence of adverse events between the combined therapy and WM. However, the conclusion that CHM was superior to WM cannot be drawn due to the inconsistent results.Conclusion: Despite that CHM has the potential benefit and safety in the adjuvant treatment of psoriasis, the conclusion should be treated with caution because of the generally low quality of methodology and evidence. In the future, high-quality randomized controlled trials (RCTs) should be carried out, and the quality of relevant SRs should also be improved to promote their clinical application.
first_indexed 2024-12-16T10:05:50Z
format Article
id doaj.art-947dcb6c8a894ef4a0c542b33b8679f6
institution Directory Open Access Journal
issn 1663-9812
language English
last_indexed 2024-12-16T10:05:50Z
publishDate 2021-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Pharmacology
spelling doaj.art-947dcb6c8a894ef4a0c542b33b8679f62022-12-21T22:35:41ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-07-011210.3389/fphar.2021.680172680172Benefits and Safety of Chinese Herbal Medicine in Treating Psoriasis: An Overview of Systematic ReviewsJie Zhang0Jie Zhang1Qianying Yu2Li Peng3Li Peng4Yuesi Qin5Mingyi Jing6Mingyi Jing7Dan Huang8Dan Huang9Jing Guo10Min Xiao11Mingling Chen12Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaChengdu University of Traditional Chinese Medicine, Chengdu, ChinaHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaChengdu University of Traditional Chinese Medicine, Chengdu, ChinaChengdu Integrated TCM and Western Medicine Hospital, Chengdu, ChinaHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaChengdu University of Traditional Chinese Medicine, Chengdu, ChinaHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaChengdu University of Traditional Chinese Medicine, Chengdu, ChinaHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaHospital of Chengdu University of Traditional Chinese Medicine, Chengdu, ChinaBackground: In recent years, systematic reviews/meta-analyses (SRs/MAs) of Chinese herbal medicine (CHM) for psoriasis have continuously emerged. Their methods and evidence quality, however, are yet to be evaluated, and whether their conclusions can provide clinicians with reliable evidence is still debatable.Objectives: This overview aims to evaluate the methodological quality, risk of bias, and reporting quality of relevant SRs/MAs, as well as the current evidence of CHM for treating psoriasis.Methods: We searched nine electronic databases from their respective time of establishment to January 20, 2021, as well as the reference lists of the included SRs/MAs, protocol registries, and gray literature. Two reviewers independently used the following: A Measurement Tool to Assess Systematic Reviews (AMSTAR) 2, Risk of Bias in Systematic Reviews (ROBIS), the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA), and Grades of Recommendations, Assessment, Development and Evaluation (GRADE) to evaluate the methodological quality, risk of bias, reporting quality, and evidence quality of the included SRs/MAs.Results: This review included 14 SRs/MAs involving 45 outcomes, of which 12 (85.71%) SRs/MAs had a very low quality evaluated by AMSTAR 2 and 7 (50.00%) SRs/MAs had a high risk of bias assessed by ROBIS. The protocol and registration and funding statements were the major reporting flaws according to the PRISMA checklist. The evaluation with the GRADE system demonstrated no outcome of high-quality evidence, and inconsistent efficacy evaluations were found in this overview. Only 15 (33.33%) outcomes were moderate-quality evidence, supporting the claim that CHM plus Western medicine (WM) was superior to WM. Generally low quality of evidence showed no difference in the incidence of adverse events between the combined therapy and WM. However, the conclusion that CHM was superior to WM cannot be drawn due to the inconsistent results.Conclusion: Despite that CHM has the potential benefit and safety in the adjuvant treatment of psoriasis, the conclusion should be treated with caution because of the generally low quality of methodology and evidence. In the future, high-quality randomized controlled trials (RCTs) should be carried out, and the quality of relevant SRs should also be improved to promote their clinical application.https://www.frontiersin.org/articles/10.3389/fphar.2021.680172/fullChinese herbal medicinepsoriasissystematic reviewAMSTAR-2ROBISPRISMA
spellingShingle Jie Zhang
Jie Zhang
Qianying Yu
Li Peng
Li Peng
Yuesi Qin
Mingyi Jing
Mingyi Jing
Dan Huang
Dan Huang
Jing Guo
Min Xiao
Mingling Chen
Benefits and Safety of Chinese Herbal Medicine in Treating Psoriasis: An Overview of Systematic Reviews
Frontiers in Pharmacology
Chinese herbal medicine
psoriasis
systematic review
AMSTAR-2
ROBIS
PRISMA
title Benefits and Safety of Chinese Herbal Medicine in Treating Psoriasis: An Overview of Systematic Reviews
title_full Benefits and Safety of Chinese Herbal Medicine in Treating Psoriasis: An Overview of Systematic Reviews
title_fullStr Benefits and Safety of Chinese Herbal Medicine in Treating Psoriasis: An Overview of Systematic Reviews
title_full_unstemmed Benefits and Safety of Chinese Herbal Medicine in Treating Psoriasis: An Overview of Systematic Reviews
title_short Benefits and Safety of Chinese Herbal Medicine in Treating Psoriasis: An Overview of Systematic Reviews
title_sort benefits and safety of chinese herbal medicine in treating psoriasis an overview of systematic reviews
topic Chinese herbal medicine
psoriasis
systematic review
AMSTAR-2
ROBIS
PRISMA
url https://www.frontiersin.org/articles/10.3389/fphar.2021.680172/full
work_keys_str_mv AT jiezhang benefitsandsafetyofchineseherbalmedicineintreatingpsoriasisanoverviewofsystematicreviews
AT jiezhang benefitsandsafetyofchineseherbalmedicineintreatingpsoriasisanoverviewofsystematicreviews
AT qianyingyu benefitsandsafetyofchineseherbalmedicineintreatingpsoriasisanoverviewofsystematicreviews
AT lipeng benefitsandsafetyofchineseherbalmedicineintreatingpsoriasisanoverviewofsystematicreviews
AT lipeng benefitsandsafetyofchineseherbalmedicineintreatingpsoriasisanoverviewofsystematicreviews
AT yuesiqin benefitsandsafetyofchineseherbalmedicineintreatingpsoriasisanoverviewofsystematicreviews
AT mingyijing benefitsandsafetyofchineseherbalmedicineintreatingpsoriasisanoverviewofsystematicreviews
AT mingyijing benefitsandsafetyofchineseherbalmedicineintreatingpsoriasisanoverviewofsystematicreviews
AT danhuang benefitsandsafetyofchineseherbalmedicineintreatingpsoriasisanoverviewofsystematicreviews
AT danhuang benefitsandsafetyofchineseherbalmedicineintreatingpsoriasisanoverviewofsystematicreviews
AT jingguo benefitsandsafetyofchineseherbalmedicineintreatingpsoriasisanoverviewofsystematicreviews
AT minxiao benefitsandsafetyofchineseherbalmedicineintreatingpsoriasisanoverviewofsystematicreviews
AT minglingchen benefitsandsafetyofchineseherbalmedicineintreatingpsoriasisanoverviewofsystematicreviews